文献速递胸部心血管CT

韩国低剂量肺癌筛查CT上的冠状动脉钙化:视觉与人工智能评估及其与心血管事件的关联

Coronary Artery Calcification on Low-Dose Lung Cancer Screening CT in South Korea: Visual and Artificial Intelligence-Based Assessment and Association With Cardiovascular Events.
PubMed 文献 · AJR Am J Roentgenol · 2024-05-29

该回顾性研究纳入1002例在韩国两个医疗中心接受低剂量肺癌筛查CT的患者,用视觉分析和两种人工智能软件评估冠状动脉钙化的存在与严重程度,并分析其与主要不良心血管事件的关联。结果显示,无论采用视觉分析还是人工智能软件评估,主要不良心血管事件发生率均随冠状动脉钙化严重程度增加而显著升高。

要点

  • 低剂量肺癌筛查CT上冠状动脉钙化检出率较高,共识视觉评估为53.4%,人工智能软件I为60.1%,软件II为56.6%。
  • 冠状动脉钙化严重程度越高,主要不良心血管事件发生率越高,视觉评估下无、轻度、中度、重度钙化分别为1.1%、5.0%、2.9%、8.6%(p < .001)。
  • 两种人工智能软件评估下主要不良心血管事件发生率亦随钙化严重程度增加而升高(p < .001)。

核心结论

  • 在韩国国家肺癌筛查项目中,无论采用视觉分析还是人工智能软件评估,主要不良心血管事件发生率均随冠状动脉钙化严重程度增加而显著升高。

研究设计与样本

  • 回顾性研究,纳入2017年4月至2023年5月在韩国两个医疗中心接受低剂量肺癌筛查CT的1002例患者(平均年龄62.4 ± 5.4岁;994例男性,8例女性),由两名放射科医生独立进行视觉评估,分歧由第三名放射科医生裁决,另用两种人工智能软件评估冠状动脉钙化,通过电子病历审查确定主要不良心血管事件。

诊断标准与关键数值

  • 冠状动脉钙化存在和严重程度的读者间一致性(kappa)分别为0.793和0.671;共识视觉评估下冠状动脉钙化患病率为53.4%,人工智能软件I为60.1%,软件II为56.6%;共识视觉评估下轻、中、重度钙化分别占28.0%、10.3%、15.1%,软件I分别占39.9%、14.0%、6.2%,软件II分别占34.9%、14.3%、7.3%;在625例有随访的患者中(中位随访1108天),36例(5.6%)发生主要不良心血管事件;共识视觉评估下无、轻、中、重度钙化的主要不良心血管事件发生率分别为1.1%、5.0%、2.9%、8.6%(p < .001),软件I分别为1.3%、3.0%、7.9%、11.3%(p < .001),软件II分别为1.2%、3.4%、7.7%、9.6%(p < .001)。

临床应用与阅片要点

  • 研究结论指出,研究结果为参与制定和监督国家肺癌筛查项目的医疗从业者提供了参考数据,强调常规评估冠状动脉钙化的重要性。

局限性

  • 研究受限于韩国国家肺癌筛查项目中较大的性别失衡。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

英文原文(摘要)· 点击展开

BACKGROUND. Coronary artery calcification (CAC) on lung cancer screening low-dose chest CT (LDCT) is a cardiovascular risk marker. South Korea was the first Asian country to initiate a national LDCT lung cancer screening program, although CAC-related outcomes are poorly explored. OBJECTIVE. The purpose of this article is to evaluate CAC prevalence and severity using visual analysis and artificial intelligence (AI) methods and to characterize CAC's association with major adverse cardiovascular events (MACEs) in patients undergoing LDCT in Korea's national lung cancer screening program. METHODS. This retrospective study included 1002 patients (mean age, 62.4 ± 5.4 [SD] years; 994 men, eight women) who underwent LDCT at two Korean medical centers between April 2017 and May 2023 as part of Korea's national lung cancer screening program. Two radiologists independently assessed CAC presence and severity using visual analysis, consulting a third radiologist to resolve differences. Two AI software applications were also used to assess CAC presence and severity. MACE occurrences were identified by EMR review. RESULTS. Interreader agreement for CAC presence and severity, expressed as kappa, was 0.793 and 0.671, respectively. CAC prevalence was 53.4% by consensus visual assessment, 60.1% by AI software I, and 56.6% by AI software II. CAC severity was mild, moderate, and severe by consensus visual analysis in 28.0%, 10.3%, and 15.1%; by AI software I in 39.9%, 14.0%, and 6.2%; and by AI software II in 34.9%, 14.3%, and 7.3%. MACEs occurred in 36 of 625 (5.6%) patients with follow-up after LDCT (median, 1108 days). MACE incidence in patients with no, mild, moderate, and severe CAC for consensus visual analysis was 1.1%, 5.0%, 2.9%, and 8.6%, respectively (p < .001); for AI software I, it was 1.3%, 3.0%, 7.9%, and 11.3% (p < .001); and for AI software II, it was 1.2%, 3.4%, 7.7%, and 9.6% (p < .001). CONCLUSION. For Korea's national lung cancer screening program, MACE occurrence increased significantly with increasing CAC severity, whether assessed by visual analysis or AI software. The study is limited by the large sex imbalance for Korea's national lung cancer screening program. CLINICAL IMPACT. The findings provide reference data for health care practitioners engaged in developing and overseeing national lung cancer screening programs, highlighting the importance of routine CAC evaluation.

来源:AJR Am J Roentgenol,查看原文。版权归原作者所有。

引用

  1. Park C, Lee BC, Jeong WG, et al. Coronary Artery Calcification on Low-Dose Lung Cancer Screening CT in South Korea: Visual and Artificial Intelligence-Based Assessment and Association With Cardiovascular Events. AJR Am J Roentgenol. 2024. PMID: 38447024. doi:10.2214/AJR.24.30852

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。